Merck KGAA Ramps Up Immuno-Oncology R&D To Close Ground On Rivals
This article was originally published in The Pink Sheet Daily
Executive Summary
The German company is looking to strengthen its cancer immunotherapy portfolio by establishing a dedicated research unit and increasing business development in the field.